MRK Stock Recent News
MRK LATEST HEADLINES
BEIJING--(BUSINESS WIRE)-- #AntibodyDrugDiscovery--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP).
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Merck advances growth with phase III pipeline backed by positive data for its potential first oral PCSK9 inhibitor.
"Dogs of the Dow" is a classic investment strategy. The idea is to find top-tier companies whose stocks are trading at unusually low prices, presumably for temporary reasons.
DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for its Healthcare business sector. Weinreich is a highly-regarded biopharma leader with extensive experience and a proven track record in R&D. He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career. In addition,.
Drugmaker Merck's oral drug met the main goal of reducing bad cholesterol in a late-stage trial, it said on Tuesday, marking a second win for the drug since June.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Enlicitide is the first oral PCSK9 inhibitor to demonstrate statistically significant and clinically meaningful reductions in LDL-C in Phase 3.
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference.
My watchlist outperformed SPY and VYM since July 1st, offering higher yield and competitive total returns, despite trailing benchmarks year-to-date. The strategy focuses on high-quality, attractively valued, high-yield stocks, aiming for a long-term CAGR of 12% and strong dividend growth. Since inception, the watchlist achieved a 15.61% CAGR and an 83.5% success rate in positive returns, validating the stock selection process.
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Provides New Results for Vericiguat in Patients with Chronic Heart Failure and Reduced Ejection Fraction. Results presented at ESC 2025.